Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telmisartan/hydrochlorothiazide

Drug Profile

Telmisartan/hydrochlorothiazide

Alternative Names: BIBR 277HCT; Kinzalkomb; Micardis Plus; MicardisPlus 80/25; Micombi; Pritor Plus

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Astellas Pharma; Bayer; Boehringer Ingelheim Pharma KG
  • Class Antihypertensives; Benzimidazoles; Benzoates; Benzothiadiazines; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Sep 2017 Chemical structure information added
  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan/hydrochlorothiazide (Micardis® family) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top